Why Regulatory Convergence is Key to Global Development of Cell and Gene Therapies

Francesco Lanucara | Senior Manager Regulatory Affairs CMC

There is growing excitement about the potential shown
by cell and gene therapies, particularly in rare diseases. First, though, these therapies face challenges both in development and in aligning to regulatory guidance that was established long before the advent of advanced therapeutic medicinal products (ATMPs).

Start a conversation today